Stocks Hitting 52-Week Highs
Medivation (NASDAQ: MDVN) shares touched a new 52-week high of $86.54 after the company and Astellas reported final results from the Phase 3 PREVAIL trial of Enzalutamide. Credit Suisse lifted the price target on Medivation from $80.00 to $95.00.
Teva Pharmaceutical Industries (NYSE: TEVA) shares reached a new 52-week high of $45.60 after the company reported the FDA approval of three-times-a-week COPAXONE 40mg/mL.
CBRE Group (NYSE: CBG) shares jumped 1.54% to touch a new 52-week high of $27.06. CBRE Group is expected release its Q4 financial results on February 5, 2014.
Jones Lang LaSalle (NYSE: JLL) shares surged 5.69% to reach a new 52-week high of $112.36 after the company reported stronger-than-expected Q4 results.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.